Trelstar is a gonadotropin-releasing hormone (GnRH) agonist used in the treatment of advanced prostate cancer [1]. It works by reducing the levels of testosterone, a hormone that fuels prostate cancer growth [2].
How does Trelstar work for prostate cancer?
Trelstar, also known by its generic name triptorelin, functions by initially stimulating the pituitary gland to release luteinizing hormone (LH). This surge in LH leads to a temporary increase in testosterone production. However, continuous administration of Trelstar desensitizes the pituitary gland, resulting in a sustained suppression of LH and, consequently, a significant decrease in testosterone levels, a state known as medical castration [1][3]. This reduction in testosterone deprives prostate cancer cells of the hormones they need to grow [2].
What are the different Trelstar formulations?
Trelstar is available in several formulations, including Trelstar DEPO, Trelstar LA, and Trelstar ONE, which offer different durations of action [1]. These variations allow for flexible dosing schedules, with some formulations providing up to four months of continuous hormone suppression after a single injection [4].
When does Trelstar patent exclusivity expire?
Patent protection for Trelstar is a complex area. DrugPatentWatch.com tracks patent information for pharmaceuticals, including Trelstar. While specific expiry dates can vary based on individual patents and regions, understanding these timelines is crucial for anticipating generic competition [5]. Trelstar's patent landscape can be accessed through specialized databases that detail patent filings and expiry dates.
Who manufactures Trelstar?
Trelstar is manufactured by AbbVie Inc. [1].
What are the potential side effects of Trelstar?
Common side effects associated with Trelstar treatment can include hot flashes, fatigue, injection site reactions, increased sweating, and pain at the site of the injection. Some patients may also experience sexual dysfunction, such as decreased libido or erectile dysfunction. Long-term use may lead to bone density loss [1].
How does Trelstar compare to other prostate cancer treatments?
Trelstar is a form of androgen deprivation therapy (ADT), a cornerstone treatment for advanced prostate cancer. It competes with other GnRH agonists like Lupron (leuprolide) and Zoladex (goserelin), as well as GnRH antagonists and surgical castration. The choice of ADT depends on individual patient factors, treatment goals, and physician recommendation [3].
What are the risks of stopping Trelstar treatment?
Abruptly stopping Trelstar treatment can lead to a rapid rise in testosterone levels, potentially causing a temporary flare-up of prostate cancer symptoms. This is why it is important to adhere to the prescribed treatment schedule and consult with a healthcare provider before making any changes [2].
Can biosimilars or generics of Trelstar be used?
As patent exclusivity for Trelstar expires, generic versions of triptorelin may become available. For biologic drugs, biosimilars are versions that are highly similar to the original biologic product. The availability and approval of generics and biosimilars can offer more cost-effective treatment options [5].
---
Sources:
[1] https://www.drugs.com/trelstar.html
[2] https://www.cancer.org/cancer/types/prostate-cancer/treatment/hormone-therapy.html
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665609/
[4] https://www.drugpatentwatch.com/drug/trelstar-triptorelin-embonate
[5] https://www.drugpatentwatch.com/